Subchronic toxicity of human immunodeficiency virus and tuberculosis combination therapies in B6C3F1 mice

Toxicological Sciences

Volumn 45, Issue 1, 1998, Pages 113-127

  Rao, Ghanta N ^a   Lindamood III, Charles ^b   Heath, James E ^b   Farnell, Daniel R ^b   Giles, Herschell D ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC TOXICITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; LIVER MICROSOME; LIVER TOXICITY; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; THROMBOCYTOSIS; TUBERCULOSIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031754315     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1006/toxs.1998.2488     Document Type: Article

References (32)

1. Amin, N. M. (1989). Zidovudine for treating AIDS. Postgrad. Med. 86, 195-208.
2. Balea, T., Marche, C., and Marche, J. (1970). Effects of hepato-biliavies de l'association rifampicine-isoniazide. Therappie 25, 125-127.
3. Balzarini, J. (1994). Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16, 113-126.
4. Baron, D. N., and Bell, J. L. (1974). Serum enzyme changes in patients receiving antituberculosis therapy with rifampin or p-aminosalicylic acid, plus isoniazid and streptomycin. Tuberecle 55, 115-120.
5. Benson, W. M., Stefko, P. L., and Roe, M. D. (1952). Pharmacological and toxicological observations on hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid). Am. Rev. Tuberculosis 65, 376-391.
6. Berenbaum, M. C. (1985). The expected effect of a combination of agents: The general solution. J. Theor. Biol. 114, 413-431.
7. Blakemore, W. F. (1980). Isoniazid. Neurotoxicology 17, 476-489.
8. Buffington, G. A., Dominguez, J. H., Piering, W. F., Herbert, L. A., Kouffman, H. M., and Lemann, J. (1976). Interaction of rifampin and glucocorticoids. J. Am. Med. Assoc. 236, 1958-1960.
9. Carter, W. H., Jr., Gennings, C., Staniswalis, J. G., Campbell, E. D., and White, K. L., Jr. (1988). A statistical approach to the construction and analysis of isobolograms. J. Am. Coll. Toxicol. 7, 963-973.
10. Dunnett, C. W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.
11. Eaton, D. L., and Klaassen, C. D. (1996). Principles of toxicology. In Casarett and Doull's Toxicology: The Basic Science of Poisions (C. D. Klaassen, Ed.), 5th ed., pp. 16-17. McGraw-Hill, New York.
12. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219-244.
13. Furesz, S. (1970). Chemical and biological properties of rifampicin. Antibiot. Chemother. 16, 316-351.
14. Gennings, C., Carter, W. H., Jr., Campbell, E. D., Staniswalis, J. G., Martin, T. J., Martin, B. R., and White, K. L., Jr. (1990). Isobolographic characterization of drug interactions incorporating biological variability. J. Pharmacol. Exp. Ther. 252, 208-217.
15. Grosset, J., and Leventis, S. (1983). Adverse effects of rifampin. Rev. Infect. Dis. 5(Suppl. 3), S440-S446.
16. Grosset, J., Truffot-Pernot, C., and Ji, B. (1992). Anatagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36, 545-551.
17. Mandell, G. L., and Sande, M. A. (1990). Drugs used in the chemotherapy of tuberculosis and leprosy. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (A. G. Gilman, T. W. Rall, A. S. Nies, and P. Tylor, Eds.), pp. 1146-1164. Pergamon Press, New York.
18. Menon, M. M., and Bhide, S. V. (1980). Transplacental, biological, and metabolic effects of isoniazid in mice and rats. Indian J. Exp. Biol. 18, 1104-1106.
19. Menon, M. M., and Bhide, S. V. (1983). Perinatal carcinogenicity of isoniazid (INH) in Swiss mice. J. Cancer Res. Clin. Oncol. 105, 258-261.
20. National Institute of Environmental Health Sciences (1997). Reproductive, Developmental, and General Toxicity Studies of Pyrazinamide Administered by Gavage to Swiss (CD-1®) Mice. NIEHS AIDS Therapeutics Toxicity Report No. 1 (NIH Publication 97-3938). U. S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
21. National Research Council (1985). Guide for the Care and Use of Laboratory Animals (NIH Publ. No. 85-23). U.S. Govt. Printing Office, Washington, DC.
22. Ohnhaus, E. E., Kirchhof, B., and Peheim, E. (1979). Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin. Clin. Pharmacol. Ther. 25, 591-597.
23. O'Reilly, R. A. (1975). Interaction of chronic daily warfarin therapy and rifampin. Ann. Intern. Med. 83, 506-508.
24. Ottoboni, M. A. (1991). The Dose Makes the Poison, 2nd ed., p. 32. Van Nostrand Reinhold, New York.
25. Pluda, J. M., Mitsuya, H., and Yarchoan, R. (1991). Hematologic effects of AIDS therapies. Hematol. Oncol. Clin. North Am. 5, 229-248.
26. Ramakrishnan, C. V., Janardhanam, B., Krishnamurthy, D. V., Stott, H., Subbammal, S., and Tripathy, S. P. (1968). Toxicity of pyrazinamide administered once weekly in high dosage in tuberculosis patients. Bull WHO 39, 775-779.
27. Richman, D. D. (1988). The treatment of HIV infection. Azidothymidine (AZT) and other new antiviral drugs. Infect. Dis. Clin. North Am. 2, 397-497.
28. Roberts, J. M., and Bourne, H. R. (1982). Drug receptors & pharmacodynamics. In Basic & Clinical Pharmacology (B. G. Katzung, Ed.), p. 18. Lange Medical, Los Altos, CA.
29. Scheuer, P. J., Summerfield, J. A., Lai, S., and Scherlock, S. (1974). Rifampin hepatitis. Lancet 1, 421-425.
30. Snedecor, G. W., and Cochran, W. G. (1967). Statistical Methods, 6th ed., pp. 272-273. Iowa State Univ. Press, Ames.
31. Thompson, M. B., Dunnick, J. K., Sutphin, M. E., Giles, H. D., Irwin, R. D., and Prejean, J. D. (1991). Hematological toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fundam. Appl. Toxicol. 17, 159-176.
32. Timbrell, J. A. (1981). Isoniazid metabolism in relation to hepatotoxicity. In Drug Reactions in the Liver (M. Davis, J. M. Tredger, and R. Williams, Eds.), pp. 190-196. Pitman Medical, London.